These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27919501)

  • 1. Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis.
    Petersen ER; Søndergaard HB; Oturai AB; Jensen P; Sorensen PS; Sellebjerg F; Börnsen L
    Mult Scler Relat Disord; 2016 Nov; 10():66-72. PubMed ID: 27919501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
    Plavina T; Muralidharan KK; Kuesters G; Mikol D; Evans K; Subramanyam M; Nestorov I; Chen Y; Dong Q; Ho PR; Amarante D; Adams A; De Sèze J; Fox R; Gold R; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Hartung HP; Cree BAC
    Neurology; 2017 Oct; 89(15):1584-1593. PubMed ID: 28916537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin α-4-transduced outside-in signalling.
    Haarmann A; Nowak E; Deiß A; van der Pol S; Monoranu CM; Kooij G; Müller N; van der Valk P; Stoll G; de Vries HE; Berberich-Siebelt F; Buttmann M
    Acta Neuropathol; 2015 May; 129(5):639-52. PubMed ID: 25814153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Matrix Metalloproteinases Panel in Multiple Sclerosis Patients Treated with Natalizumab: A Possible Answer to Natalizumab Non- Responders.
    Balasa R; Bianca C; Septimiu V; Iunius S; Adina H; Sebastian A; Andreea R; Anca M; Smaranda M
    CNS Neurol Disord Drug Targets; 2018; 17(6):464-472. PubMed ID: 29968546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab treatment reduces endothelial activity in MS patients.
    Millonig A; Hegen H; Di Pauli F; Ehling R; Gneiss C; Hoelzl M; Künz B; Lutterotti A; Rudzki D; Berger T; Reindl M; Deisenhammer F
    J Neuroimmunol; 2010 Oct; 227(1-2):190-4. PubMed ID: 20739072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab.
    Auer M; Bauer A; Oftring A; Rudzki D; Hegen H; Bsteh G; Di Pauli F; Berek K; Zinganell A; Berger T; Reindl M; Deisenhammer F
    CNS Drugs; 2022 Oct; 36(10):1121-1131. PubMed ID: 36173556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy.
    Castellazzi M; Bellini T; Trentini A; Delbue S; Elia F; Gastaldi M; Franciotta D; Bergamaschi R; Manfrinato MC; Volta CA; Granieri E; Fainardi E
    Dis Markers; 2016; 2016():8434209. PubMed ID: 27340316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
    Novakova L; Axelsson M; Malmeström C; Zetterberg H; Björkhem I; Karrenbauer VD; Lycke J
    J Neurol Sci; 2015 Nov; 358(1-2):201-6. PubMed ID: 26342940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis.
    Villani S; Zanotta N; Ambrogi F; Comar M; Franciotta D; Dolci M; Cason C; Ticozzi R; Ferrante P; Delbue S
    J Neuroimmunol; 2017 Sep; 310():91-96. PubMed ID: 28778452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention.
    van Langelaar J; van der Vuurst de Vries RM; Janssen M; Wierenga-Wolf AF; Spilt IM; Siepman TA; Dankers W; Verjans GMGM; de Vries HE; Lubberts E; Hintzen RQ; van Luijn MM
    Brain; 2018 May; 141(5):1334-1349. PubMed ID: 29659729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.
    Börnsen L; Christensen JR; Ratzer R; Oturai AB; Sørensen PS; Søndergaard HB; Sellebjerg F
    PLoS One; 2012; 7(11):e47578. PubMed ID: 23226199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab Changes the Peripheral Profile of the Th17 Panel in MS Patients: New Mechanisms of Action.
    Balasa RI; Simu M; Voidazan S; Barcutean LI; Bajko Z; Hutanu A; Simu I; Maier S
    CNS Neurol Disord Drug Targets; 2017; 16(9):1018-1026. PubMed ID: 28782487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.
    Sehr T; Proschmann U; Thomas K; Marggraf M; Straube E; Reichmann H; Chan A; Ziemssen T
    J Neuroinflammation; 2016 Jun; 13(1):164. PubMed ID: 27349895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab reduces serum pro-angiogenic activity in MS patients.
    Iaffaldano P; Ribatti D; Trojano M
    Neurol Sci; 2018 Apr; 39(4):725-731. PubMed ID: 29441483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies.
    Axelsson M; Dubuisson N; Novakova L; Malmeström C; Giovannoni G; Lycke J; Gnanapavan S
    Acta Neurol Scand; 2019 May; 139(5):422-427. PubMed ID: 30657162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
    Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
    Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.
    Órpez-Zafra T; Pavía J; Hurtado-Guerrero I; Pinto-Medel MJ; Rodriguez Bada JL; Urbaneja P; Suardíaz M; Villar LM; Comabella M; Montalban X; Alvarez-Cermeño JC; Leyva L; Fernández Ó; Oliver-Martos B
    Mult Scler; 2017 Jun; 23(7):937-945. PubMed ID: 27613121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis.
    Bitsch A; Bahner D; Wachter C; Elitok E; Bogumil T; Dressel A; Polak T; Tumani H; Weber F; Poser S; Kitze B
    Acta Neurol Scand; 2004 Dec; 110(6):386-92. PubMed ID: 15527451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis.
    Rieckmann P; Altenhofen B; Riegel A; Kallmann B; Felgenhauer K
    Mult Scler; 1998 Jun; 4(3):178-82. PubMed ID: 9762670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The frequency of occurrence of atypical lymphocytes in peripheral blood smears of natalizumab-treated patients with multiple sclerosis.
    Robier C; Amouzadeh-Ghadikolai O; Bregant C; Diez J; Melinz K; Quehenberger F; Quasthoff S
    Int J Lab Hematol; 2017 Oct; 39(5):469-474. PubMed ID: 28481019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.